EXEL - 2 No-Brainer Biotech Stocks to Buy Right Now
2023-08-24 07:30:00 ET
Following the market's gloomy 2022, this year has been a breath of fresh air with the S&P 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. C ystic fibrosis specialist Vertex Pharmaceuticals (NASDAQ: VRTX) has risen 19% in 2023, while cancer specialist Exelixis (NASDAQ: EXEL) has gained 31% -- and both medical areas are likely to see strong demand for a long time to come.
Let's see why these two stocks could make good additions to investors' portfolios now.
Image source: Getty Images.
For further details see:
2 No-Brainer Biotech Stocks to Buy Right Now